Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Jacob T. Brown; Jeffrey R. Bishop; Katrin Sangkuhl; Erika L. Nurmi; Daniel J. Mueller; Jean C Dinh; Andrea Gaedigk; Teri E. Klein; Kelly E. Caudle; James T. McCracken; Jose de Leon; J.  Steven Leeder

doi:10.1002/cpt.1409

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Jacob T. Brown, Jeffrey R. Bishop, Katrin Sangkuhl, Erika L. Nurmi, Daniel J. Mueller, Jean C Dinh, Andrea Gaedigk, Teri E. Klein, Kelly E. Caudle, James T. McCracken, Jose de Leon, J. Steven Leeder

Research output: Contribution to journal › Review article › peer-review

126 Scopus citations

Abstract

Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

Original language	English (US)
Pages (from-to)	94-102
Number of pages	9
Journal	Clinical pharmacology and therapeutics
Volume	106
Issue number	1
DOIs	https://doi.org/10.1002/cpt.1409
State	Published - Jul 2019

Bibliographical note

Publisher Copyright:
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics

Access

10.1002/cpt.1409

OpenUrl availability

Full text

Cite this

Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, JC., Gaedigk, A., Klein, T. E., Caudle, K. E., McCracken, J. T., de Leon, J., & Leeder, J. S. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clinical pharmacology and therapeutics, 106(1), 94-102. https://doi.org/10.1002/cpt.1409

Brown, JT , Bishop, JR, Sangkuhl, K, Nurmi, EL, Mueller, DJ, Dinh, JC, Gaedigk, A, Klein, TE, Caudle, KE, McCracken, JT, de Leon, J & Leeder, JS 2019, 'Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy', Clinical pharmacology and therapeutics, vol. 106, no. 1, pp. 94-102. https://doi.org/10.1002/cpt.1409

@article{fddd7b6413f8472099b0b62bd8912003,

title = "Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy",

abstract = "Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).",

author = "Brown, {Jacob T.} and Bishop, {Jeffrey R.} and Katrin Sangkuhl and Nurmi, {Erika L.} and Mueller, {Daniel J.} and Jean C Dinh and Andrea Gaedigk and Klein, {Teri E.} and Caudle, {Kelly E.} and McCracken, {James T.} and {de Leon}, Jose and Leeder, {J. Steven}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors Clinical Pharmacology & Therapeutics {\textcopyright} 2019 American Society for Clinical Pharmacology and Therapeutics",

year = "2019",

month = jul,

doi = "10.1002/cpt.1409",

language = "English (US)",

volume = "106",

pages = "94--102",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

AU - Brown, Jacob T.

AU - Bishop, Jeffrey R.

AU - Sangkuhl, Katrin

AU - Nurmi, Erika L.

AU - Mueller, Daniel J.

AU - Dinh, Jean C

AU - Gaedigk, Andrea

AU - Klein, Teri E.

AU - Caudle, Kelly E.

AU - McCracken, James T.

AU - de Leon, Jose

AU - Leeder, J. Steven

PY - 2019/7

Y1 - 2019/7

N2 - Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

AB - Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).

UR - http://www.scopus.com/inward/record.url?scp=85064476155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064476155&partnerID=8YFLogxK

U2 - 10.1002/cpt.1409

DO - 10.1002/cpt.1409

M3 - Review article

C2 - 30801677

AN - SCOPUS:85064476155

SN - 0009-9236

VL - 106

SP - 94

EP - 102

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 1

ER -

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this